StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.00−0.08 (-0.44%)

Close on Nov 17, 2026Market cap $2.88BP/E –Yield –

Denali Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Denali Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$434.04M. For fiscal 2025 it was -$412.60M. The highest annual figure on record is $416.15M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$412.60M–
FY2024Dec 31, 2024-$347.69M–
FY2023Dec 31, 2023-$357.99M–
FY2022Dec 31, 2022-$244.72M–
FY2021Dec 31, 2021-$211.39M-150.8%
FY2020Dec 31, 2020$416.15M–
FY2019Dec 31, 2019-$151.58M-402.5%
FY2018Dec 31, 2018$50.12M–
FY2017Dec 31, 2017-$76.64M–
FY2016Dec 31, 2016-$71.91M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$97.00M–
Q1 FY2026Mar 31, 2026-$131.20M–
Q4 FY2025Dec 31, 2025-$98.54M–
Q3 FY2025Sep 30, 2025-$107.30M–
Q2 FY2025Jun 30, 2025-$75.30M–
Q1 FY2025Mar 31, 2025-$131.47M–
Q4 FY2024Dec 31, 2024-$83.72M–
Q3 FY2024Sep 30, 2024-$59.14M–
Q2 FY2024Jun 30, 2024-$91.22M–
Q1 FY2024Mar 31, 2024-$113.62M–
Q4 FY2023Dec 31, 2023-$98.66M–
Q3 FY2023Sep 30, 2023-$87.36M–
Q2 FY2023Jun 30, 2023-$113.17M–
Q1 FY2023Mar 31, 2023-$58.80M–
Q4 FY2022Dec 31, 2022-$72.66M–
Q3 FY2022Sep 30, 2022-$57.05M–
Q2 FY2022Jun 30, 2022-$42.90M–
Q1 FY2022Mar 31, 2022-$72.11M–
Q4 FY2021Dec 31, 2021-$65.49M-112.7%
Q3 FY2021Sep 30, 2021-$41.43M-48279.1%
Q2 FY2021Jun 30, 2021-$54.22M–
Q1 FY2021Mar 31, 2021-$50.24M–
Q4 FY2020Dec 31, 2020$513.92M–
Q3 FY2020Sep 30, 2020$86.00K–
Q2 FY2020Jun 30, 2020-$43.36M–
Q1 FY2020Mar 31, 2020-$54.49M–
Q4 FY2019Dec 31, 2019-$47.64M-151.1%
Q3 FY2019Sep 30, 2019-$30.44M–
Q2 FY2019Jun 30, 2019-$43.18M–
Q1 FY2019Mar 31, 2019-$30.32M-190.3%
Q4 FY2018Dec 31, 2018$93.19M–
Q3 FY2018Sep 30, 2018-$34.82M–
Q2 FY2018Jun 30, 2018-$41.82M–
Q1 FY2018Mar 31, 2018$33.58M–
Q4 FY2017Dec 31, 2017-$18.34M–
Q3 FY2017Sep 30, 2017-$21.92M–
Q2 FY2017Jun 30, 2017-$17.57M–
Q1 FY2017Mar 31, 2017-$18.81M–

More Denali Therapeutics figures

See a number that looks wrong?